Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

When it comes to the U.S. biopharma market, pricing seems to be the driving focus of most congressional conversations – and ...

People using the popular weight loss injections including Ozempic and Wegovy could be more at risk of osteoporosis and bone ...

This adds to BioDlink's portfolio of international GMP approvals, following recent certifications in Brazil, Indonesia, Egypt ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

Marijuana and THC edibles were both linked to changes in vascular endothelial function associated with early development of ...